Candoxatril

Cat. No.: HY-19649
CAS No.: 123122-55-4
Molecular Formula: C₂₉H₄₁NO₇
Molecular Weight: 515.64
Target: Neprilysin
Pathway: Metabolic Enzyme/Protease
Storage: Please store the product under the recommended conditions in the COA.

BIOLOGICAL ACTIVITY

<table>
<thead>
<tr>
<th>Description</th>
<th>Candoxatril is a neutral endopeptidase (NEP) inhibitor.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC₅₀ &amp; Target</td>
<td>NEP[1].</td>
</tr>
<tr>
<td>In Vivo</td>
<td>While the NEP inhibitors have no significant effect on body weight, food and water intake, mean blood pressure or creatinine levels, they do increase cGMP levels in the urine and affected hematopoiesis in an anti-inflammatory way. Moreover, α-SMA deposition in the kidney cortex is inversely correlated with cGMP elevation suggesting a NEP dependent antifibrotic effect. High quality mRNA profiles are obtained with at least 8 independent samples per treatment group. The data confirms the cGMP dependent anti-fibrotic action of Sol-1 and further supports the potential therapeutic actions of this neutral endopeptidase inhibitor[2].</td>
</tr>
</tbody>
</table>

PROTOCOL

| Animal Administration | Mice[2] (n=10 per group) subjected to UUO are treated for 1 week with either Solvent, SOL-1 (NEP-/ECE-inhibitor two doses), Candoxatril (reference NEP inhibitor) or losartan (angiotensin AT1-receptor antagonist) and compared to sham operated animals[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

